查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1672126

全球慢性特發性便秘治療市場研究報告-產業分析、規模、佔有率、成長、趨勢和預測 2025 年至 2033 年

Global Chronic Idiopathic Constipation Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
出版日期: | 出版商: Value Market Research | 英文 158 Pages | 商品交期: 最快1-2個工作天內

價格

全球慢性特發性便秘治療市場規模預計將從 2024 年的 36.3 億美元成長到 2033 年的 67.7 億美元，在 2026 年至 2033 年的預測期內呈現 7.17% 的強勁年複合成長率(CAGR)。

隨著胃腸道疾病的盛行率不斷上升以及人們對可用治療方案的認知不斷提高，慢性特發性便秘治療市場有望大幅成長。慢性特發性便秘（CIC）是一種常見疾病，其特徵是排便不頻繁和排便困難，會嚴重影響患者的生活品質。隨著醫療保健提供者尋求改善患者治療結果並加強對 CIC 的管理，對有效療法（包括瀉藥、處方藥和飲食干預）的需求預計將上升，從而使該市場實現強勁擴張。

此外，CIC 治療方案的進步正在推動市場創新。鳥苷酸環化酶-C激動劑和血清素受體激動劑等新型藥物的開發擴大了 CIC 的治療前景，為患者提供了更有效、更有針對性的治療選擇。這些創新不僅改善了腸道功能，也解決了便秘的根本機制，並提高了患者的整體滿意度。隨著研究不斷探索新的療法和聯合療法，慢性特發性便秘治療市場可能會進一步擴大，這得益於改善患者護理和生活品質的前景。

此外，人們對生活方式的改變和預防保健的日益重視正在塑造慢性特發性便秘的治療模式。隨著醫療保健提供者越來越認知到飲食、補水和體力活動在管理 CIC 中的重要性，對教育資源和支持計劃的需求可能會增加。這種積極主動的方法不僅使患者能夠控制自己的病情，而且還促進了患者和醫療保健提供者之間的合作關係。隨著市場不斷發展，創新療法、病患教育和對生活方式介入的關注將在推動其未來成長中發揮關鍵作用。

我們的報告經過精心製作，為客戶提供有關各個行業和市場的全面且可操作的見解。每份報告都包含幾個關鍵部分，以確保徹底了解市場格局：

市場概覽：市場的詳細介紹，包括定義、分類和行業現狀概述。

市場動態：深入分析影響市場成長的關鍵促進因素、限制因素、機會與挑戰。本節探討技術進步、監管變化和新興趨勢等因素。

細分分析：根據產品類型、應用、最終用戶和地理位置等標準將市場細分為不同的細分市場。該分析強調了每個部分的表現和潛力。

競爭格局：對主要市場參與者的全面評估，包括其市場佔有率、產品組合、策略舉措和財務表現。本節深入介紹領先公司的競爭動態和關鍵策略。

市場預測：根據歷史資料和當前市場狀況，預測特定時期內的市場規模和成長趨勢。這包括定量分析和圖形表示來說明未來的市場軌跡。

區域分析：評估不同地理區域的市場表現，確定關鍵市場和區域趨勢。這有助於了解區域市場動態和機會。

新興趨勢與機會：識別當前和新興的市場趨勢、技術創新和潛在投資領域。本節提供未來市場發展和成長前景的見解。

目錄

第 1 章：前言

  • 報告描述
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究流程
    • 市場研究方法

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：慢性特發性便秘治療產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業趨勢
  • 波特五力分析
  • 市場吸引力分析
    • 按類型分析市場吸引力
    • 按治療類型進行的市場吸引力分析
    • 依治療類型進行市場吸引力分析
    • 藥品市場吸引力分析
    • 按給藥途徑進行的市場吸引力分析
    • 最終用戶的市場吸引力分析
    • 按配銷通路進行的市場吸引力分析
    • 市場吸引力分析：按地區

第4章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料製造商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球慢性特發性便秘治療市場分析：按類型

  • 按類型概覽
  • 按類型進行的歷史和預測資料分析
  • 正常傳輸性便秘
  • 慢速傳輸型便秘
  • 其他

第 6 章：全球慢性特發性便秘治療市場分析：依治療類型

  • 按治療類型概述
  • 按治療類型進行的歷史和預測數據分析
  • 藥物治療
  • 非藥物治療

第 7 章：全球慢性特發性便秘治療市場分析：依治療類型

  • 按治療類型概述
  • 按治療類型進行的歷史和預測數據分析
  • 藥物
  • 手術

第 8 章：全球慢性特發性便秘治療市場分析：按藥物

  • 藥物概覽
  • 按藥物進行的歷史和預測數據分析
  • 5-羥色胺-4（5-HT4）受體激動劑
  • 鳥苷酸環化酶-C 激動劑
  • 瀉藥
  • 興奮劑
  • 其他

第 9 章：全球慢性特發性便秘治療市場分析：依給藥途徑

  • 依給藥途徑概述
  • 按給藥途徑進行的歷史和預測數據分析
  • 口服
  • 注射劑

第 10 章：全球慢性特發性便秘治療市場分析：依最終用戶

  • 最終用戶概覽
  • 最終用戶的歷史和預測數據分析
  • 醫院
  • 居家護理
  • 專科診所
  • 其他

第 11 章：全球慢性特發性便秘治療市場分析：按通路

  • 按配銷通路概覽
  • 按配銷通路進行的歷史和預測資料分析
  • 醫院藥房
  • 零售藥局
  • 其他

第 12 章：全球慢性特發性便秘治療市場分析：按地區分類

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概述、歷史和預測數據銷售分析
    • 北美各細分市場銷售分析
    • 北美各國銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概述、歷史和預測數據銷售分析
    • 歐洲各細分市場銷售分析
    • 歐洲各國銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概述、歷史和預測數據銷售分析
    • 亞太地區分部銷售分析
    • 亞太地區國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概述、歷史和預測數據銷售分析
    • 拉丁美洲各細分市場銷售分析
    • 拉丁美洲各國銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概述、歷史和預測數據銷售分析
    • 中東和非洲分部銷售分析
    • 中東和非洲國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東和非洲其他地區銷售分析

第 13 章：慢性特發性便秘治療公司的競爭格局

  • 慢性特發性便秘治療市場競爭
  • 夥伴關係/合作/協議
  • 合併與收購
  • 新產品發布
  • 其他進展

第 14 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • ALLERGAN
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Mallinckrodt Plc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Synergy Pharmaceuticals Inc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Takeda Pharmaceutical Company Limited
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Sanofi
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Zydus Cadila
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Boehringer Ingelheim International GmbH
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Shreya Life Sciences Pvt Ltd
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Abbott
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • GSK Plc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Troikaa Pharmaceuticals Ltd
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Lupin
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • East West Pharma
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Ironwood Pharmaceuticals Inc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，對於私人公司，可能不予涵蓋

Product Code: VMR11214173

Global Chronic Idiopathic Constipation Treatment Market size is anticipated to grow from USD 3.63 Billion in 2024 to USD 6.77 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.17% during the forecast period of 2026 to 2033.

The chronic idiopathic constipation treatment market is poised for significant growth, driven by the increasing prevalence of gastrointestinal disorders and the rising awareness of available treatment options. Chronic idiopathic constipation (CIC) is a common condition characterized by infrequent bowel movements and difficulty in passing stools, which can significantly impact patients' quality of life. As healthcare providers seek to improve patient outcomes and enhance the management of CIC, the demand for effective therapies, including laxatives, prescription medications, and dietary interventions, is expected to rise, positioning this market for robust expansion.

Moreover, advancements in treatment options for CIC are driving innovation within the market. The development of novel pharmacological agents, such as guanylate cyclase-C agonists and serotonin receptor agonists, has expanded the therapeutic landscape for CIC, offering patients more effective and targeted treatment options. These innovations not only improve bowel function but also address the underlying mechanisms of constipation, enhancing overall patient satisfaction. As research continues to explore new therapies and combination treatments, the chronic idiopathic constipation treatment market is likely to expand further, driven by the promise of improved patient care and quality of life.

Additionally, the growing emphasis on lifestyle modifications and preventive care is shaping the chronic idiopathic constipation treatment landscape. As healthcare providers increasingly recognize the importance of diet, hydration, and physical activity in managing CIC, the demand for educational resources and support programs is likely to increase. This proactive approach not only empowers patients to take control of their condition but also fosters a collaborative relationship between patients and healthcare providers. As the market continues to evolve, the combination of innovative therapies, patient education, and a focus on lifestyle interventions will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Type

  • Normal-transit constipation
  • Slow-transit constipation
  • Others

By Therapy Type

  • Pharmacological Therapy
  • Non-pharmacological Therapy

By Treatment Type

  • Medication
  • Surgery

By Drugs

  • Serotonin-4 (5-Ht4) Receptor Agonist
  • Guanylate Cyclase-C Agonist
  • Laxatives
  • Stimulants
  • Others

By Route of Administration

  • Oral
  • Injectable

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • COMPANIES PROFILED
  • ALLERGAN
  • Mallinckrodt plc
  • Synergy Pharmaceuticals Inc
  • Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Zydus Cadila
  • Boehringer Ingelheim International GmbH
  • Shreya Life Sciences Pvt Ltd
  • Abbott
  • GSK plc
  • Troikaa Pharmaceuticals Ltd
  • Lupin
  • East West Pharma
  • Ironwood Pharmaceuticals Inc.
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Therapy Type
    • 3.7.3 Market Attractiveness Analysis By Treatment Type
    • 3.7.4 Market Attractiveness Analysis By Drugs
    • 3.7.5 Market Attractiveness Analysis By Route of Administration
    • 3.7.6 Market Attractiveness Analysis By End-Users
    • 3.7.7 Market Attractiveness Analysis By Distribution Channel
    • 3.7.8 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY TYPE

  • 5.1. Overview By Type
  • 5.2. Historical and Forecast Data Analysis By Type
  • 5.3. Normal-transit constipation Historic and Forecast Sales By Regions
  • 5.4. Slow-transit constipation Historic and Forecast Sales By Regions
  • 5.5. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY THERAPY TYPE

  • 6.1. Overview By Therapy Type
  • 6.2. Historical and Forecast Data Analysis By Therapy Type
  • 6.3. Pharmacological Therapy Historic and Forecast Sales By Regions
  • 6.4. Non-pharmacological Therapy Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

  • 7.1. Overview By Treatment Type
  • 7.2. Historical and Forecast Data Analysis By Treatment Type
  • 7.3. Medication Historic and Forecast Sales By Regions
  • 7.4. Surgery Historic and Forecast Sales By Regions

8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY DRUGS

  • 8.1. Overview By Drugs
  • 8.2. Historical and Forecast Data Analysis By Drugs
  • 8.3. Serotonin-4 (5-Ht4) Receptor Agonist Historic and Forecast Sales By Regions
  • 8.4. Guanylate Cyclase-C Agonist Historic and Forecast Sales By Regions
  • 8.5. Laxatives Historic and Forecast Sales By Regions
  • 8.6. Stimulants Historic and Forecast Sales By Regions
  • 8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 9.1. Overview By Route of Administration
  • 9.2. Historical and Forecast Data Analysis By Route of Administration
  • 9.3. Oral Historic and Forecast Sales By Regions
  • 9.4. Injectable Historic and Forecast Sales By Regions

10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY END-USERS

  • 10.1. Overview By End-Users
  • 10.2. Historical and Forecast Data Analysis By End-Users
  • 10.3. Hospitals Historic and Forecast Sales By Regions
  • 10.4. Homecare Historic and Forecast Sales By Regions
  • 10.5. Specialty Clinics Historic and Forecast Sales By Regions
  • 10.6. Others Historic and Forecast Sales By Regions

11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 11.1. Overview By Distribution Channel
  • 11.2. Historical and Forecast Data Analysis By Distribution Channel
  • 11.3. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 11.4. Retail Pharmacies Historic and Forecast Sales By Regions
  • 11.5. Others Historic and Forecast Sales By Regions

12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 12.1. Regional Outlook
  • 12.2. Introduction
  • 12.3. North America Sales Analysis
    • 12.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.3.2 North America By Segment Sales Analysis
    • 12.3.3 North America By Country Sales Analysis
    • 12.3.4 United States Sales Analysis
    • 12.3.5 Canada Sales Analysis
    • 12.3.6 Mexico Sales Analysis
  • 12.4. Europe Sales Analysis
    • 12.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.4.2 Europe By Segment Sales Analysis
    • 12.4.3 Europe By Country Sales Analysis
    • 12.4.4 United Kingdom Sales Analysis
    • 12.4.5 France Sales Analysis
    • 12.4.6 Germany Sales Analysis
    • 12.4.7 Italy Sales Analysis
    • 12.4.8 Russia Sales Analysis
    • 12.4.9 Rest Of Europe Sales Analysis
  • 12.5. Asia Pacific Sales Analysis
    • 12.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.5.2 Asia Pacific By Segment Sales Analysis
    • 12.5.3 Asia Pacific By Country Sales Analysis
    • 12.5.4 China Sales Analysis
    • 12.5.5 India Sales Analysis
    • 12.5.6 Japan Sales Analysis
    • 12.5.7 South Korea Sales Analysis
    • 12.5.8 Australia Sales Analysis
    • 12.5.9 South East Asia Sales Analysis
    • 12.5.10 Rest Of Asia Pacific Sales Analysis
  • 12.6. Latin America Sales Analysis
    • 12.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.6.2 Latin America By Segment Sales Analysis
    • 12.6.3 Latin America By Country Sales Analysis
    • 12.6.4 Brazil Sales Analysis
    • 12.6.5 Argentina Sales Analysis
    • 12.6.6 Peru Sales Analysis
    • 12.6.7 Chile Sales Analysis
    • 12.6.8 Rest of Latin America Sales Analysis
  • 12.7. Middle East & Africa Sales Analysis
    • 12.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.7.2 Middle East & Africa By Segment Sales Analysis
    • 12.7.3 Middle East & Africa By Country Sales Analysis
    • 12.7.4 Saudi Arabia Sales Analysis
    • 12.7.5 UAE Sales Analysis
    • 12.7.6 Israel Sales Analysis
    • 12.7.7 South Africa Sales Analysis
    • 12.7.8 Rest Of Middle East And Africa Sales Analysis

13. COMPETITIVE LANDSCAPE OF THE CHRONIC IDIOPATHIC CONSTIPATION TREATMENT COMPANIES

  • 13.1. Chronic Idiopathic Constipation Treatment Market Competition
  • 13.2. Partnership/Collaboration/Agreement
  • 13.3. Merger And Acquisitions
  • 13.4. New Product Launch
  • 13.5. Other Developments

14. COMPANY PROFILES OF CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY

  • 14.1. Top Companies Market Share Analysis
  • 14.2. Market Concentration Rate
  • 14.3. ALLERGAN
    • 14.3.1 Company Overview
    • 14.3.2 Company Revenue
    • 14.3.3 Products
    • 14.3.4 Recent Developments
  • 14.4. Mallinckrodt Plc
    • 14.4.1 Company Overview
    • 14.4.2 Company Revenue
    • 14.4.3 Products
    • 14.4.4 Recent Developments
  • 14.5. Synergy Pharmaceuticals Inc
    • 14.5.1 Company Overview
    • 14.5.2 Company Revenue
    • 14.5.3 Products
    • 14.5.4 Recent Developments
  • 14.6. Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
    • 14.6.1 Company Overview
    • 14.6.2 Company Revenue
    • 14.6.3 Products
    • 14.6.4 Recent Developments
  • 14.7. Takeda Pharmaceutical Company Limited
    • 14.7.1 Company Overview
    • 14.7.2 Company Revenue
    • 14.7.3 Products
    • 14.7.4 Recent Developments
  • 14.8. Sanofi
    • 14.8.1 Company Overview
    • 14.8.2 Company Revenue
    • 14.8.3 Products
    • 14.8.4 Recent Developments
  • 14.9. Zydus Cadila
    • 14.9.1 Company Overview
    • 14.9.2 Company Revenue
    • 14.9.3 Products
    • 14.9.4 Recent Developments
  • 14.10. Boehringer Ingelheim International GmbH
    • 14.10.1 Company Overview
    • 14.10.2 Company Revenue
    • 14.10.3 Products
    • 14.10.4 Recent Developments
  • 14.11. Shreya Life Sciences Pvt Ltd
    • 14.11.1 Company Overview
    • 14.11.2 Company Revenue
    • 14.11.3 Products
    • 14.11.4 Recent Developments
  • 14.12. Abbott
    • 14.12.1 Company Overview
    • 14.12.2 Company Revenue
    • 14.12.3 Products
    • 14.12.4 Recent Developments
  • 14.13. GSK Plc
    • 14.13.1 Company Overview
    • 14.13.2 Company Revenue
    • 14.13.3 Products
    • 14.13.4 Recent Developments
  • 14.14. Troikaa Pharmaceuticals Ltd
    • 14.14.1 Company Overview
    • 14.14.2 Company Revenue
    • 14.14.3 Products
    • 14.14.4 Recent Developments
  • 14.15. Lupin
    • 14.15.1 Company Overview
    • 14.15.2 Company Revenue
    • 14.15.3 Products
    • 14.15.4 Recent Developments
  • 14.16. East West Pharma
    • 14.16.1 Company Overview
    • 14.16.2 Company Revenue
    • 14.16.3 Products
    • 14.16.4 Recent Developments
  • 14.17. Ironwood Pharmaceuticals Inc
    • 14.17.1 Company Overview
    • 14.17.2 Company Revenue
    • 14.17.3 Products
    • 14.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Type (USD MN)
  • Normal-transit constipation Market Sales By Geography (USD MN)
  • Slow-transit constipation Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Therapy Type (USD MN)
  • Pharmacological Therapy Market Sales By Geography (USD MN)
  • Non-pharmacological Therapy Market Sales By Geography (USD MN)
  • Analysis By Treatment Type (USD MN)
  • Medication Market Sales By Geography (USD MN)
  • Surgery Market Sales By Geography (USD MN)
  • Analysis By Drugs (USD MN)
  • Serotonin-4 (5-Ht4) Receptor Agonist Market Sales By Geography (USD MN)
  • Guanylate Cyclase-C Agonist Market Sales By Geography (USD MN)
  • Laxatives Market Sales By Geography (USD MN)
  • Stimulants Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Analysis By End-Users (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Homecare Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Chronic Idiopathic Constipation Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Chronic Idiopathic Constipation Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Chronic Idiopathic Constipation Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Therapy Type
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Drugs
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By End-Users
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Type (USD MN)
  • Normal-transit constipation Market Sales By Geography (USD MN)
  • Slow-transit constipation Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Therapy Type (USD MN)
  • Pharmacological Therapy Market Sales By Geography (USD MN)
  • Non-pharmacological Therapy Market Sales By Geography (USD MN)
  • Global Market Analysis By Treatment Type (USD MN)
  • Medication Market Sales By Geography (USD MN)
  • Surgery Market Sales By Geography (USD MN)
  • Global Market Analysis By Drugs (USD MN)
  • Serotonin-4 (5-Ht4) Receptor Agonist Market Sales By Geography (USD MN)
  • Guanylate Cyclase-C Agonist Market Sales By Geography (USD MN)
  • Laxatives Market Sales By Geography (USD MN)
  • Stimulants Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Global Market Analysis By End-Users (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Homecare Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.